SCHEMBL7010031

SCHEMBL7010031

O=S(=O)(NCCCCCCNc1nsc2nccn12)c1ccccc1Cl

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F13A1 P00488 10/20 0.78
TGM1 P22735 4/20 0.73
NR3C2 P08235 1/20 0.42
CYP3A4 P08684 6/20 0.40
CYP1A2 P05177 5/20 0.40
CYP2C19 P33261 5/20 0.40
CYP2C9 P11712 4/20 0.40
TDP1 Q9NUW8 3/20 0.40
MAPK1 P28482 3/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TP53 P04637 5/20 0.39
TSHR P16473 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CYP2D6 P10635 3/20 0.39
THPO P40225 2/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
FPR2 P25090 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7003300 0.93 F13A1 (0.74) F13A1TGM1CYP3A4CYP1A2CYP2C19
SCHEMBL7008310 0.90 F13A1 (0.76) F13A1TGM1NR3C2CYP3A4CYP1A2
SCHEMBL7007822 0.90 F13A1 (0.75) F13A1TGM1CYP3A4CYP1A2CYP2C19
SCHEMBL7014440 0.89 F13A1 (0.80) F13A1TGM1ALDH1A1KDM4ELMNA
SCHEMBL7008818 0.88 F13A1 (0.67) F13A1TGM1ALDH1A1MAPTCCR1
SCHEMBL7004031 0.88 F13A1 (0.67) F13A1TGM1MEN1KMT2AMAPT
SCHEMBL7006075 0.88 F13A1 (0.78) F13A1TGM1CYP3A4CYP1A2CYP2C19
SCHEMBL7009337 0.88 F13A1 (0.78) F13A1TGM1NR3C2CYP3A4CYP1A2
SCHEMBL7008678 0.88 F13A1 (1.00) F13A1TGM1NR3C2ALDH1A1NPY5R
SCHEMBL7005641 0.86 F13A1 (0.65) F13A1TGM1NR3C2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases APOTEX INC. 2003-12-04 US disclosed
EP-1348710-A1 Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases Apotex Inc. (CA) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225007-A1 Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases PIGS, FGB, SERPINE1 F13A1 14/4885TGM1 7/4885NR3C2 4776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.